Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...
almost all patients progress to castration-resistant prostate cancer (CRPC). The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling ...
Results from the phase 3 PEACE-3 study found that a combination therapy showed higher benefits for patients with bone ...
As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in ...
Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...
Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...
13d
Explore our latest breakthroughs in metastatic prostate cancer research. Learn more about our innovative pipeline today! @ ...
There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...
Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor ...
In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback